Skip to main content

Achieve Life Sciences, Inc 8-K, filed Nov 10, 2026

Achieve Life Sciences, Inc. (QUIT)

8-K 2026-11-10 For: 2026-11-10
View Original
Added on November 10, 2026

About this 8-K

Achieve Life Sciences, Inc filed this 8-K on November 10, 2026.

AchieveRx reported cash, cash equivalents, and marketable securities of $201.5 million as of September 30, 2026. Cytisinicline’s NDA resubmission remains on track for the fourth quarter of 2026; third-quarter net loss was $12.1 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits